Cargando…

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC

Detalles Bibliográficos
Autores principales:	Strickland, Matthew R., Jänne, Pasi A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791198/ https://www.ncbi.nlm.nih.gov/pubmed/33437811 http://dx.doi.org/10.21037/atm-20-4253

Ejemplares similares

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
por: Ding, Caixia, et al.
Publicado: (2023)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis
por: Lu, Daniel, et al.
Publicado: (2022)

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
por: Seto, Takashi, et al.
Publicado: (2021)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping
por: Chen, Hualin, et al.
Publicado: (2022)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations
por: Paik, Paul K., et al.
Publicado: (2022)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
por: Daniel, Catherine, et al.
Publicado: (2020)

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC
por: Cravero, Paola, et al.
Publicado: (2020)

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
por: Lau, Sally C.M., et al.
Publicado: (2023)

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION
por: Bestvina, Christine M, et al.
Publicado: (2021)

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION
por: Leighl, Natasha, et al.
Publicado: (2022)

MET exon 14 skipping is overexpressed in an allele-specific manner in lung adenocarcinoma primary samples
por: Durham, Megan, et al.
Publicado: (2023)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
por: Kim, So Yeon, et al.
Publicado: (2022)

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study
por: Liu, Xue-wen, et al.
Publicado: (2020)

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021)

Recurrent PTPRZ1‐MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases
por: Chai, Rui‐Chao, et al.
Publicado: (2021)

The devil's in the details
por: Petsko, Gregory A
Publicado: (2010)

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study
por: Sakai, Hiroshi, et al.
Publicado: (2021)

MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?
por: Pruis, Melinda A., et al.
Publicado: (2020)

Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer
por: Al Jaberi, Mira, et al.
Publicado: (2023)

Commentary: The devil is in the details
por: Falasa, Matheus P., et al.
Publicado: (2021)

Commentary: The devil is in the details
por: Coselli, Joseph S., et al.
Publicado: (2020)

Cholesterol-Binding Sites in GIRK Channels: The Devil is in the Details
por: Rosenhouse-Dantsker, Avia
Publicado: (2018)

Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline MET Exon 14 Skipping Mutation: A Case Report
por: Jiao, Yang, et al.
Publicado: (2021)

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
por: Le, Xiuning, et al.
Publicado: (2022)

Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report
por: Liu, Zhicong, et al.
Publicado: (2023)

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
por: Drilon, Alexander, et al.
Publicado: (2020)

The devil is in the details: Genomics of transmissible cancers in Tasmanian devils
por: Storfer, Andrew, et al.
Publicado: (2018)

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
por: Yan, S. Betty, et al.
Publicado: (2017)

Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors
por: Nishio, Makoto, et al.
Publicado: (2022)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
por: Jie, Guang-Ling, et al.
Publicado: (2023)

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
por: Sohn, Sung-Hwa, et al.
Publicado: (2022)

Epigenetics and obesity: the devil is in the details
por: Franks, Paul W, et al.
Publicado: (2010)

Intermittent Catheterization: The Devil Is in the Details
por: Christison, Kathleen, et al.
Publicado: (2018)

Neuropsychiatric Lupus: The Devil is in the Detail
por: Elavarasi, Arunmozhimaran, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_51rier68cigcbjprn9d7hub5jk